539730 FREDUN

Fredun Pharmaceuticals Share Price

 

 

Start SIP in FREDUN

Start SIP

Performance

  • Low
  • ₹1,510
  • High
  • ₹1,627
  • 52 Week Low
  • ₹635
  • 52 Week High
  • ₹1,999
  • Open Price₹1,550
  • Previous Close₹1,536
  • Volume13,315

Investment Returns

  • Over 1 Month -18.18%
  • Over 3 Month + 19.24%
  • Over 6 Month + 96.28%
  • Over 1 Year + 111.9%

Smart Investing Starts Here Start SIP with Fredun Pharmaceuticals for Steady Growth!

Invest Now

Fredun Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 25.9
  • PEG Ratio
  • 0.4
  • Market Cap Cr
  • 748
  • P/B Ratio
  • 4.7
  • Average True Range
  • 102.35
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -25.74
  • RSI
  • 41.93
  • MFI
  • 43.54

Fredun Pharmaceuticals Financials

Fredun Pharmaceuticals Technicals

EMA & SMA

Current Price
₹1,584.90
+ 48.65 (3.17%)
pointer
  • Bearish Moving Average 11
  • Bullish Moving Average 5
  • 20 Day
  • ₹1,670.71
  • 50 Day
  • ₹1,655.36
  • 100 Day
  • ₹1,505.78
  • 200 Day
  • ₹1,277.76

Resistance and Support

1573.97 Pivot Speed
  • R3 1,754.93
  • R2 1,690.97
  • R1 1,637.93
  • S1 1,520.93
  • S2 1,456.97
  • S3 1,403.93

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Fredun Pharmaceuticals has an operating revenue of Rs. 428.43 Cr. on a trailing 12-month basis. An annual revenue growth of 31% is outstanding, Pre-tax margin of 6% is okay, ROE of 14% is good. The company has a reasonable debt to equity of 7%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 35% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 98 which is a GREAT score indicating consistency in earnings, a RS Rating of 95 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at C which is evident from recent supply seen, Group Rank of 76 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of A is the best. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Fredun Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-08 Quarterly Results
2025-09-25 Preferential Issue of shares & Others To consider 1. Issue Of Warrants. alia, to consider a proposal for fund raising up to Rs.120 crores by way of further public offer, rights issue, debt issue, preferential issue or any other method.
2025-07-30 Quarterly Results
2025-05-30 Audited Results & Dividend
2025-02-04 Quarterly Results
Date Purpose Remarks
2025-09-23 FINAL Rs.0.70 per share(7%)Dividend
2024-09-23 FINAL Rs.0.70 per share(7%)Final Dividend
2023-09-22 FINAL Rs.0.70 per share(7%)Final Dividend
2022-09-15 FINAL Rs.0.70 per share(7%)Final Dividend
View Fredun Pharmaceuticals Dividend History Arrow

Fredun Pharmaceuticals F&O

Fredun Pharmaceuticals Shareholding Pattern

48.93%
0.01%
1.59%
43.74%
5.73%

About Fredun Pharmaceuticals

  • NSE Symbol
  • FREDUN
  • BSE Symbol
  • 539730
  • Managing Director & CFO
  • Mr. Fredun Medhora
  • ISIN
  • INE194R01017

Similar Stocks to Fredun Pharmaceuticals

Fredun Pharmaceuticals FAQs

Fredun Pharmaceuticals share price is ₹1,584 As on 03 January, 2026 | 10:43

The Market Cap of Fredun Pharmaceuticals is ₹748.3 Cr As on 03 January, 2026 | 10:43

The P/E ratio of Fredun Pharmaceuticals is 25.9 As on 03 January, 2026 | 10:43

The PB ratio of Fredun Pharmaceuticals is 4.7 As on 03 January, 2026 | 10:43

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23